Effect of the novel sigma1 receptor ligand and putative atypical antipsychotic E-5842 on BDNF mRNA expression in the rat brain

NeuroReport

Volumn 13, Issue 17, 2002, Pages 2345-2348

  Ovalle, Sergio ^a   Andreu, Francesc ^a   Pérez, M Pilar ^a   Zamanillo, Daniel ^a   Guitart, Xavier ^a  

^a Research Center   (Spain)

Author keywords

Atypical antipsychotic; Brain derived neurotrophic factor; E 5842; Neurotrophin; Rat frontal cortex; Schizophrenia

Indexed keywords

4 (4 FLUOROPHENYL) 1,2,3,6 TETRAHYDRO 1 [4 (1,2,4 TRIAZOL 1 YL)BUTYL]PYRIDINE; ATYPICAL ANTIPSYCHOTIC AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; LIGAND; MESSENGER RNA; NERVE GROWTH FACTOR; NEUROTROPHIN; SIGMA 1 OPIATE RECEPTOR; NEUROLEPTIC AGENT; PYRIDINE DERIVATIVE; SIGMA OPIATE RECEPTOR; SIGMA-1 RECEPTOR; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN; BRAIN LEVEL; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; FRONTAL CORTEX; HIPPOCAMPUS; LONG TERM EXPOSURE; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RAT; REGULATORY MECHANISM; STIMULATION; TISSUE DISTRIBUTION; ANIMAL; COGNITIVE DEFECT; FRONTAL LOBE; GENETICS; METABOLISM; NEOSTRIATUM; NERVE CELL; PATHOPHYSIOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT; SYNAPTIC TRANSMISSION;

ANIMALS; ANTIPSYCHOTIC AGENTS; BRAIN; BRAIN-DERIVED NEUROTROPHIC FACTOR; DELIRIUM, DEMENTIA, AMNESTIC, COGNITIVE DISORDERS; DOWN-REGULATION; FRONTAL LOBE; HIPPOCAMPUS; MALE; NEOSTRIATUM; NERVE GROWTH FACTOR; NEURONS; PYRIDINES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SIGMA; RNA, MESSENGER; SYNAPTIC TRANSMISSION; TRIAZOLES;

EID: 0037015832     PISSN: 09594965     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001756-200212030-00035     Document Type: Article

References (24)

1. Huang EJ and Reichard LF. Annu Rev Neurosci 24, 677-736 (2001).
2. Alberch J, Brito B, Notario V and Castro R. Neurosci Left 131, 228-232 (1991).
3. Angelucci F, Mathé AA and Aloe L. J Neurosci Res 60, 783-794 (2000).
4. Linden AM, Väisänen J, Lakso M et al. J Mol Neurosci 14, 27-37 (2000).
5. Hohon A, Leibrock J, Bailey K and Barde YA. Nature 344, 339-341 (1990).
6. Altar CA. Trends Pharmacol Sci 20, 59-61 (1999).
7. Nibuya M, Morinobu S and Duman RS. J Neurosci 15, 7539-7547 (1995).
8. Duman RS, Heninger GR and Nestler EJ. Arch Gen Psychiatry 54, 597-606 (1997).
9. Fukumoto T, Morinobu S, Okamoto Y et al. Psychopharmacology 158, 100-106 (2001).
10. Brouha AK, Shannon Weickert C, Hyde TM et al. Soc Neurosci Abstr 22, 1680 (1996).
11. Takahashi M, Shirakawa O, Toyooka K et al. Mol Psychiatry 5, 293-300 (2000).
12. Lipska BK, Khaing ZZ, Shannon Weickert C and Weinberger DR. Eur J Neurosci 14, 135-144 (2001).
13. Chlan-Fourney J, Li X-M, Juorio AV et al. Soc Neurosci Abstr 24, 754 (1998).
14. Riva MA, Molteni R, Tascedda F et al. Neuropharmacology 38, 1075-1082 (1999).
15. Guitart X, Ballarín M, Codony X et al. Drugs of the Future 24, 386-392 (1999).
16. Guitart X, Farré AJ. Eur J Pharmacol 363, 127-130 (1998).
17. Sánchez-Arroyos R, Guitart X. Eur J Pharmacol 378, 31-33 (1999).
18. Ovalle S, Zamanillo D, Andreu F et al. Eur J Neurosci 13, 909-915 (2001).
19. Chomczynski P and Sacchi N. Anal Biochem 162, 156-159 (1987).
20. Russo-Neustadt A, Beard RC and Cotman CW. Neuropsychopharmacology 21, 679-682, (1999).
21. Vaidya VA, Marek GJ, Aghajanian GK and Duman RS. J Neurosci 17, 2785-2795 (1997).
22. Guitart X, Méndez R, Ovalle S et al. Neuropsychopharmacology 23, 539-546 (2000).
23. Hall J, Thomas KL, Everitt BJ. Nature Neurosci 3, 533-535 (2000).
24. Phillips HS, Hains JM, Armanini M et al. Neuron 7, 695-702 (1991).